AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26
Non-myeloablative hematopoietic stem cell transplantation
Authors: Maris, M Sandmaier, BM Maloney, DG McSweeney, PA Woolfrey, A Chauncey, T Shizuru, J Niederwieser, D Blume, KG Forman, S Storb, R
Citation: M. Maris et al., Non-myeloablative hematopoietic stem cell transplantation, TRANSF CL B, 8(3), 2001, pp. 231-234
Nonmyeloablative hematopoietic stem cell transplantation: Transplantation for the 21(st) century
Authors: Maris, M Woolfrey, A McSweeney, PA Sandmaier, BM Nash, RA Georges, G Maloney, DG Molina, A Chauncey, T Yu, C Zaucha, JM Blume, KG Shizuru, J Niederwieser, D Storb, R
Citation: M. Maris et al., Nonmyeloablative hematopoietic stem cell transplantation: Transplantation for the 21(st) century, FRONT BIOSC, 6, 2001, pp. G13-G16
Mechanism of action of rituximab
Authors: Maloney, DG
Citation: Dg. Maloney, Mechanism of action of rituximab, ANTI-CANC D, 12, 2001, pp. S1-S4
Immunotherapy for non-Hodgkin's lymphoma - The Vose article reviewed
Authors: Maloney, DG
Citation: Dg. Maloney, Immunotherapy for non-Hodgkin's lymphoma - The Vose article reviewed, ONCOLOGY-NY, 15(2), 2001, pp. 153
Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens
Authors: Gutierrez-Delgado, F Maloney, DG Press, OW Golden, J Holmberg, LA Maziarz, RT Hooper, H Buckner, CD Appelbaum, FR Bensinger, WI
Citation: F. Gutierrez-delgado et al., Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens, BONE MAR TR, 28(5), 2001, pp. 455-461
Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older
Authors: Gopal, AK Gooley, TA Golden, JB Maloney, DG Bensinger, WI Petersdorf, SH Appelbaum, FR Press, OW
Citation: Ak. Gopal et al., Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older, BONE MAR TR, 27(6), 2001, pp. 593-599
Monoclonal antibody therapy for hematologic malignancies: Prospects for anintegrated approach (vol 37, pg 17, 2000)
Authors: Maloney, DG
Citation: Dg. Maloney, Monoclonal antibody therapy for hematologic malignancies: Prospects for anintegrated approach (vol 37, pg 17, 2000), SEM HEMATOL, 38(1), 2001, pp. 92-92
Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation
Authors: Storek, J Wells, D Dawson, MA Storer, B Maloney, DG
Citation: J. Storek et al., Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation, BLOOD, 98(2), 2001, pp. 489-491
Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation
Authors: Storek, J Joseph, A Espino, G Dawson, MA Douek, DC Sullivan, KM Flowers, MED Martin, P Mathioudakis, G Nash, RA Storb, R Appelbaum, FR Maloney, DG
Citation: J. Storek et al., Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation, BLOOD, 98(13), 2001, pp. 3505-3512
Decreased transfusion requirements for patients receiving nonmyeloablativecompared with conventional peripheral blood stem cell transplants from HLA-identical siblings
Authors: Weissinger, F Sandmaier, BM Maloney, DG Bensinger, WI Gooley, T Storb, R
Citation: F. Weissinger et al., Decreased transfusion requirements for patients receiving nonmyeloablativecompared with conventional peripheral blood stem cell transplants from HLA-identical siblings, BLOOD, 98(13), 2001, pp. 3584-3588
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation
Authors: Storek, J Dawson, MA Storer, B Stevens-Ayers, T Maloney, DG Marr, KA Witherspoon, RP Bensinger, W Flowers, MED Martin, P Storb, R Appelbaum, FR Boeckh, M
Citation: J. Storek et al., Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation, BLOOD, 97(11), 2001, pp. 3380-3389
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
Authors: McSweeney, PA Niederwieser, D Shizuru, JA Sandmaier, BM Molina, AJ Maloney, DG Chauncey, TR Gooley, TA Hegenbart, U Nash, RA Radich, J Wagner, JL Minor, S Appelbaum, FR Bensinger, WI Bryant, E Flowers, MED Georges, GE Grumet, FC Kiem, HP Torok-Storb, B Yu, G Blume, KG Storb, RF
Citation: Pa. Mcsweeney et al., Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects, BLOOD, 97(11), 2001, pp. 3390-3400
Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a
Authors: Davis, TA Maloney, DG Grillo-Lopez, AJ White, CA Williams, ME Weiner, GJ Dowden, S Levy, R
Citation: Ta. Davis et al., Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a, CLIN CANC R, 6(7), 2000, pp. 2644-2652
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:Safety and efficacy of re-treatment
Authors: Davis, TA Grillo-Lopez, AJ White, CA McLaughlin, P Czuczman, MS Link, BK Maloney, DG Weaver, RL Rosenberg, J Levy, R
Citation: Ta. Davis et al., Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:Safety and efficacy of re-treatment, J CL ONCOL, 18(17), 2000, pp. 3135-3143
Allogeneic hematopoietic stem cell transplantation: From the nuclear age into the twenty-first century
Authors: Storb, R McSweeney, PA Sandmaier, BM Nash, RA Georges, G Maloney, DG Molina, A Chauncey, T Yu, C Zaucha, JM Blume, KG Shizuru, J Niederwieser, D
Citation: R. Storb et al., Allogeneic hematopoietic stem cell transplantation: From the nuclear age into the twenty-first century, TRANSPLAN P, 32(7), 2000, pp. 2548-2549
Monoclonal antibodies in lymphoid neoplasia: Principles for optimal combined therapy
Authors: Maloney, DG
Citation: Dg. Maloney, Monoclonal antibodies in lymphoid neoplasia: Principles for optimal combined therapy, SEM HEMATOL, 37(4), 2000, pp. 17-26
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
Authors: Press, OW Eary, JF Gooley, T Gopal, AK Liu, S Rajendran, JG Maloney, DG Petersdorf, S Bush, SA Durack, LD Martin, PJ Fisher, DR Wood, B Borrow, JW Porter, B Smith, JP Matthews, DC Appelbaum, FR Bernstein, ID
Citation: Ow. Press et al., A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas, BLOOD, 96(9), 2000, pp. 2934-2942
Normal T, B, and NK cell counts in healthy donors at 1 year after blood stem cell harvesting
Authors: Storek, J Dawson, MA Maloney, DG
Citation: J. Storek et al., Normal T, B, and NK cell counts in healthy donors at 1 year after blood stem cell harvesting, BLOOD, 95(9), 2000, pp. 2993-2994
Normal anti-CD3-stimulated proliferation of CD4 T cells at one year after allogeneic marrow transplantation
Authors: Storek, J Dawson, MA Maloney, DG
Citation: J. Storek et al., Normal anti-CD3-stimulated proliferation of CD4 T cells at one year after allogeneic marrow transplantation, TRANSPL IMM, 7(2), 1999, pp. 123-125
Antibody therapy has arrived. Now where does it fit?
Authors: Maloney, DG
Citation: Dg. Maloney, Antibody therapy has arrived. Now where does it fit?, ANN ONCOL, 10(6), 1999, pp. 619-621
Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma:Results of a phase II trial of rituximab
Authors: Davis, TA White, CA Grillo-Lopez, AJ Velasquez, WS Link, B Maloney, DG Dillman, RO Williams, ME Mohrbacher, A Weaver, R Dowden, S Levy, R
Citation: Ta. Davis et al., Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma:Results of a phase II trial of rituximab, J CL ONCOL, 17(6), 1999, pp. 1851-1857
Preclinical and phase I and II trials of rituximab
Authors: Maloney, DG
Citation: Dg. Maloney, Preclinical and phase I and II trials of rituximab, SEMIN ONCOL, 26(5), 1999, pp. 74-78
Antibody therapy for treatment of multiple myeloma
Authors: Maloney, DG Donovan, K Hamblin, TJ
Citation: Dg. Maloney et al., Antibody therapy for treatment of multiple myeloma, SEM HEMATOL, 36(1), 1999, pp. 30-33
Large cell non-Hodgkin's lymphoma and Hodgkin's disease arising synchronously in a patient with chronic lymphocytic leukemia: Importance of immunocytochemistry
Authors: Gopal, AK Schuetze, SH Maloney, DG Weiden, PL
Citation: Ak. Gopal et al., Large cell non-Hodgkin's lymphoma and Hodgkin's disease arising synchronously in a patient with chronic lymphocytic leukemia: Importance of immunocytochemistry, BLOOD, 94(7), 1999, pp. 2537-2537
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation
Authors: Holmberg, LA Boeckh, M Hooper, H Leisenring, W Rowley, S Heimfeld, S Press, O Maloney, DG McSweeney, P Corey, L Maziarz, RT Appelbaum, FR Bensinger, W
Citation: La. Holmberg et al., Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation, BLOOD, 94(12), 1999, pp. 4029-4035
Risultati: 1-25 | 26-26